ArticleSAGE open medicine2020
Serum interferon-gamma level is associated with drug-naïve major depressive disorder.
Article in SAGE open medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 3 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Altered Cytokine Levels in the First Episode of Major Depression and in Antidepressant-Naïve Patients: A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- Activation of the interleukin-23/Th17 axis in major depression: a systematic review and meta-analysis.European archives of psychiatry and clinical neuroscience · 2025Pooled it
- Evaluation of inflammatory cytokines in drug-naïve major depressive disorder: A systematic review and meta-analysis.International journal of immunopathology and pharmacologyPooled it
- Trial
- AI-driven tripartite classification for optimizing wearable bioelectronics in depression management.Science advances · 2026Article
- Depression and breast cancer: research progress and prospects from an interdisciplinary perspective.Frontiers in immunology · 2026Review
- Cerebral Blood Flow and Blood-Brain Barrier Water Exchange in Major Depressive Disorder: Evidence from Diffusion-Prepared Arterial Spin Labelling MRI.Brain sciences · 2025Article
- Inflammatory profiles of transdiagnostic symptom dimensions in healthy females.Brain, behavior, & immunity - health · 2025Article
- Gender differences in gray matter volume of the anterior cingulate cortex and suicidal ideation in patients with major depressive disorder: evidence from the REST-meta-MDD project.Translational psychiatry · 2025Article
- Identifying behavior regulatory leverage over mental disorders transcriptomic network hubs toward lifestyle-dependent psychiatric drugs repurposing.Human genomics · 2025Article
- Structural brain changes in the anterior cingulate cortex of major depressive disorder individuals with suicidal ideation: Evidence from the REST-meta-MDD project.Psychological medicine · 2025Article
- Inflammatory proteins related to depression in multiple sclerosis: A systematic review and meta-analysis.Brain, behavior, & immunity - health · 2025Review
- Flow-cytometric analysis of immune cell populations in patients with depression: relationship with depression severity and electroconvulsive therapy therapeutic outcomes.Frontiers in cellular neuroscience · 2025Article
- Bidirectional relationship between serum creatinine to cystatin C ratio and chronic kidney disease: a mediation analysis of depression in a national aging cohort.Frontiers in psychiatry · 2025Article
- Increased serum EGF but not SDF-1 levels are associated with the pathophysiology and development of generalized anxiety disorder.Scientific reports · 2024Article
- Evaluation of serum interleukin-12 and interleukin-4 as potential biomarkers for the diagnosis of major depressive disorder.Scientific reports · 2024Article
- Serum levels of interleukin-33 and mesencephalic astrocyte derived neurotrophic factors in patients with major depressive disorder: a cross-sectional comparative design.BMC psychiatry · 2024Article
- Associations of pro-inflammatory factors and IL-10 levels with degree of suicide risk in adolescents with depression.Frontiers in psychiatry · 2024Article
- Evaluation of serum MIP-1β and MCP-2 levels in major depressive disorder: A case-control study.PloS one · 2024Article
- Investigation of the effects of oxidative stress, inflammation on the pathway of tryptophan/kynurenine in OCD.Acta neuropsychiatrica · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMajor depressive disorder is a leading heterogeneous psychiatric illness manifested by persistent low mood, a feeling of sadness, and diminished interest in daily activities. Many biological, genetic, and social factors are thought to be linked with depression. But any suitable early risk assessment markers are absent for this illness. Therefore, we aimed to investigate the serum levels of IFN-γ in major depressive disorder patients to further investigate the association between serum levels of this cytokine and major depression.
methodsThis prospective case-control study enrolled 120 major depressive disorder patients and 100 healthy controls matched by age, sex, and body mass index. A qualified psychiatrist diagnosed the major depressive disorder patients and evaluated healthy controls according to the
resultsThis study observed that serum IFN-γ levels were significantly decreased in major depressive disorder patients compared to healthy controls. A significant negative correlation (
conclusionWe suggest the altered serum IFN-γ levels are associated with the pathophysiology of depression. The reduced levels of serum IFN-γ might be used as an early risk assessment tool for major depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.